According to PhRMA’s 2012 Medicines in Development Report, more than 1,000 cancer agents are now being pursued by biopharmaceutical researchers — And among these new approaches in the fight against cancer are oral oncolytics.
An increasing proportion of all antineoplastic agents in today’s pipeline are being developed as oral drugs. Although oral chemotherapy has existed for decades, oral oncolytics are becoming a more popular therapeutic option than intravenous (IV) chemotherapy for a number of cancers. In addition to providing patients with a more convenient form of administration, many of these new agents target specific biologic processes in cancer cells and exhibit a higher degree of safety and effectiveness compared to traditional chemotherapies, which usually indiscriminately attack both cancer and healthy cells.
This is good news for oncologists and their patients; however, it comes with its own set of challenges, namely patient access and adherence.
This is because a significant part of the responsibility in managing drug regimens and monitoring for dosing/toxicity is shifted from the oncology team to the patient and/or caregiver. For some patients, having this level of direct involvement in their disease management and treatment may be empowering, while for others, this shift in responsibility can be overwhelming, especially if the appropriate family and/or caregiver support is not in place.
This webinar aims to address these oral oncology adherence challenges and overcome them.
The speakers talk about proven approaches to address these challenges through patient and caregiver engagement with the help of qualified oncology nurse educators, MSL’s and even specialized pharmaceutical reps engaging providers. This multi-team focused approach can be highly beneficial to the patients. Strategies employed specifically by the oncology nurse educators include tailored, flexible, customer based focus, comprehensive patient education regarding dosing, disease recurrence with non-medication adherence, identification and resolution of barriers to compliance all these as part of an individualized therapeutic plan.
The speakers will also discuss specific case studies to demonstrate success of this approach.
Susie Newton, RN, MS, AOCN, AOCNS, Senior Director, Health Management Solutions, Quintiles
Susie is an Oncology Advanced Practice Nurse and has worked in various nursing roles within the Pharmaceutical industry for the past 15 years. Prior to working in industry, Susie was an Oncology Clinical Nurse Specialist at community and academic centers in Ohio, Louisiana, and Florida.
At Quintiles, Susie currently oversees all Oncology and specialty teams within the Health Management Solutions division of Quintiles. Susie was previously the Director of Oncology Nursing at a major Pharmaceutical company. In this capacity, Susie led a group of 50 Oncology Nurse Educator Consultants on a 10 year program.
In 2013 Susie was elected to be Director-at-Large for the 36,000 member National Oncology Nursing Society. She will serve this term of office through 2016.
Susie has a Bachelor’s degree in Nursing from Wright State University, and a Masters degree in Oncology Nursing from the University of South Florida. She is also certified as an Advanced Oncology Certified Nurse and Nurse Specialist.
Susie has authored numerous professional articles, book chapters, and has published three nursing textbooks: “Telephone Triage for Oncology Nurses” (first and second editions) and “Telephone Triage for Otorhinolaryngology Head-Neck Nurses” published by the Oncology Nursing Society (ONS) and “Oncology Nursing Advisor” published by Elsevier. Recently lecturing in the Middle East and Japan, Susie is an internationally known speaker and thought leader within the Oncology Nursing community
Cheryl Fowler, BSN, RN, National Director, Hematology Clinical Nurse Educators
Cheryl Fowler received both her ASN and BSN coupled with a minor in German Languages from North Georgia College. Prior to Quintiles, her clinical experiences were in Oncology, Home Health, General Med Surg and Women’s Health. Cheryl has held positions as Nurse Educator, Field Manager and Director working with 6 major PhRMA companies during her tenure supporting clinical areas of diabetes, rheumatology, pain management, cardiology, respiratory, oncology and hematology. Cheryl has been the recipient of both Presidents Club and Customer Service Awards. Her professional goal is to ensure that healthcare providers receive first class services in education to assist them meet their goals in patient outcomes through the products her teams support and to that patients feel empowered and remain engaged in their care.
Nicole Korak, MSN, FNP, National Director, Oncology Clinical Nurse Educators
Nicole has 22 years of Oncology Nursing experience and started her career as a hospital oncology nurse for University of Texas Southwestern. Nicole was one of the original Oncology Nurse Navigators at Parkland Hospital for the Outpatient Clinic for newly diagnosed breast cancer patients, helping the indigent population navigate the oncology community health care system. She was one of the youngest nurses to receive the TOP 100 nurses award in 1995 for reorganizing the appointment and clinic flow to decrease the wait time from 6 hours to 2 hours.
Currently, her primary focus is oncology education, working with various Pharmaceutical companies to increase the appropriate use and side effect management of patients receiving the oncology treatments. She contributes to the information and the delivery of the education so that the content will be evidence based and valuable to oncology nurses.
Nicole is the author of two chapters in second edition of Telephone Triage for Oncology Nurses. She has written and presented various education programs approved for Continuing Education Credits by Oncology Education services, including Oncology Emergencies.
Who Should Attend?
Senior level executives involved in Oncology Therapy working within:
- Brand Management / Product management
- Health affairs
- Medical affairs
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of bioPharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in more than 100 countries, we helped develop or commercialize all of 2013’s Top 100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.